MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS) today announced that Mercy Hospital St. Louis will now offer Cologuard®, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Colorectal cancer is the second-leading cancer related cause of death in the United States and is often the most preventable. However, due to the lack of patient compliance with current screening options, it’s the least prevented cancer.
Help employers find you! Check out all the jobs and post your resume.
